111 related articles for article (PubMed ID: 9444444)
1. Safety and pharmacokinetics of the neuroprotective drug lubeluzole in patients with ischemic stroke.
De Keyser J; Van de Velde V; Schellens RL; Hantson L; Tritsmans L; Gheuens J; Van Peer A; Woestenborghs R; Franke CL; van Gorp J
Clin Ther; 1997; 19(6):1340-51. PubMed ID: 9444444
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects.
Van de Velde V; Crabbe R; Van Peer A; Woestenborghs R; Van Osselaer N; Hantson L; Heykants J
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):490-3. PubMed ID: 9760010
[TBL] [Abstract][Full Text] [Related]
3. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group.
Grotta J
Stroke; 1997 Dec; 28(12):2338-46. PubMed ID: 9412611
[TBL] [Abstract][Full Text] [Related]
4. The safety and tolerability of single intravenous doses of lubeluzole (Prosynap) in healthy volunteers.
Hantson L; Tritsmans L; Crabbé R; Gheuens J; Van Rooy P
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):491-5. PubMed ID: 9401829
[TBL] [Abstract][Full Text] [Related]
5. Determination of the dose proportionality of single intravenous doses (5, 10, and 15 mg) of lubeluzole in healthy volunteers.
Herron J; Lee P; Pesco-Koplowitz L; Gajjar D; Soo YW; Woestenborghs R
Clin Ther; 1998; 20(4):682-90. PubMed ID: 9737828
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of lubeluzole (Prosynap(R)) in patients with ischemic stroke.
Hacke W; Lees KR; Timmerhuis T; Haan J; Hantson L; Hennerici M; Diener HC
Cerebrovasc Dis; 1998; 8(5):247-54. PubMed ID: 9712921
[TBL] [Abstract][Full Text] [Related]
7. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo.
Diener HC; Cortens M; Ford G; Grotta J; Hacke W; Kaste M; Koudstaal PJ; Wessel T
Stroke; 2000 Nov; 31(11):2543-51. PubMed ID: 11062273
[TBL] [Abstract][Full Text] [Related]
8. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group.
Diener HC
Cerebrovasc Dis; 1998; 8(3):172-81. PubMed ID: 9619701
[TBL] [Abstract][Full Text] [Related]
9. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group.
Diener HC; Hacke W; Hennerici M; Rådberg J; Hantson L; De Keyser J
Stroke; 1996 Jan; 27(1):76-81. PubMed ID: 8553408
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
Grotta J;
Cerebrovasc Dis; 2001; 12(3):258-63. PubMed ID: 11641593
[TBL] [Abstract][Full Text] [Related]
11. Lubeluzole. JK 8792, R 87926, Prosynap.
Drugs R D; 1999 Jan; 1(1):29-31. PubMed ID: 10565978
[No Abstract] [Full Text] [Related]
12. Lubeluzole for acute ischaemic stroke.
Gandolfo C; Sandercock P; Conti M
Cochrane Database Syst Rev; 2002; (1):CD001924. PubMed ID: 11869612
[TBL] [Abstract][Full Text] [Related]
13. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke.
Dyker AG; Lees KR
Stroke; 1999 Sep; 30(9):1796-801. PubMed ID: 10471426
[TBL] [Abstract][Full Text] [Related]
14. Combined neuroprotection and reperfusion therapy for stroke. Effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia.
Aronowski J; Strong R; Grotta JC
Stroke; 1996 Sep; 27(9):1571-6; discussion 1576-7. PubMed ID: 8784132
[TBL] [Abstract][Full Text] [Related]
15. Effects of the antihypoxic and neuroprotective drug, lubeluzole, on repolarization phase of canine heart assessed by monophasic action potential recording.
Sugiyama A; Ni C; Arita J; Eto K; Xue YX; Hashimoto K
Toxicol Appl Pharmacol; 1996 Jul; 139(1):109-14. PubMed ID: 8685892
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study.
Diener HC; AlKhedr A; Busse O; Hacke W; Zingmark PH; Jonsson N; Basun H;
J Neurol; 2002 May; 249(5):561-8. PubMed ID: 12021946
[TBL] [Abstract][Full Text] [Related]
17. Diffusion-weighted MRI of infarct growth in a rat photochemical stroke model: effect of lubeluzole.
De Ryck M; Verhoye M; Van der Linden AM
Neuropharmacology; 2000 Feb; 39(4):691-702. PubMed ID: 10728890
[TBL] [Abstract][Full Text] [Related]
18. Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats.
De Ryck M; Keersmaekers R; Duytschaever H; Claes C; Clincke G; Janssen M; Van Reet G
J Pharmacol Exp Ther; 1996 Nov; 279(2):748-58. PubMed ID: 8930180
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental focal ischemia in rats with lubeluzole.
Aronowski J; Strong R; Grotta JC
Neuropharmacology; 1996 Jun; 35(6):689-93. PubMed ID: 8887977
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of the neuroprotectant lubeluzole on bovine and mouse chromaffin cell calcium channel subtypes.
Hernández-Guijo JM; Gandía L; de Pascual R; García AG
Br J Pharmacol; 1997 Sep; 122(2):275-85. PubMed ID: 9313936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
